The worldwide prevalence of obesity is increasing at an alarming rate, with major adverse
consequences for human health. This" obesity epidemic" is paralleled by a rapid and …

Cannabinoids—the active components of Cannabis sativa and their derivatives—exert
palliative effects in cancer patients by preventing nausea, vomiting and pain and by …

Endogenous cannabinoids acting at CB1 receptors stimulate appetite, and CB1 antagonists
show promise in the treatment of obesity. CB1–/–mice are resistant to diet-induced obesity …

During the last few years, the endocannabinoid system has emerged as a highly relevant
topic in the scientific community. Many different regulatory actions have been attributed to …

Background In animal models, cannabinoid-1 receptor (CB 1) blockade produces a lean
phenotype, with resistance to diet-induced obesity and associated dyslipidaemia. We …

Background Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been
shown to reduce body weight and improve cardiovascular risk factors in obese patients. The …

Antiobesity treatment is recommended for selected patients in whom lifestyle modification is
unsuccessful. Two antiobesity drugs are currently licensed for long-term use. Orlistat, a …

ContextRimonabant, a selective cannabinoid-1 receptor blocker, may reduce body weight
and improve cardiometabolic risk factors in patients who are overweight or obese …

The human gut is a composite anaerobic environment with a large, diverse and dynamic
enteric microbiota, represented by more than 100 trillion microorganisms, including at least …

Obesity and its metabolic consequences are a major public health concern worldwide.
Obesity is associated with overactivity of the endocannabinoid system, which is involved in …